Enhanced targeting with heterobivalent ligands - Wikidata - wikimedia - TriplyDB

Enhanced targeting with heterobivalent ligands

Enhanced targeting with heterobivalent ligands

http://www.wikidata.org/entity/Q36870878

about

Synthesis and evaluation of cholecystokinin trimers: a multivalent approach to pancreatic cancer detection and treatment Expanding the utility of beta-galactosidase complementation: piece by piece.Design and applications of bispecific heterodimers: molecular imaging and beyond Synthesis and characterization of a Eu-DTPA-PEGO-MSH(4) derivative for evaluation of binding of multivalent molecules to melanocortin receptors.Delta-Opioid Receptor (δOR) Targeted Near-Infrared Fluorescent Agent for Imaging of Lung Cancer: Synthesis and Evaluation In Vitro and In Vivo.A sucrose-derived scaffold for multimerization of bioactive peptides Identification of novel pancreatic adenocarcinoma cell-surface targets by gene expression profiling and tissue microarray Heterobivalent ligands target cell-surface receptor combinations in vivo.Peptides and peptidomimetics as immunomodulators.Development of a time-resolved fluorescence probe for evaluation of competitive binding to the cholecystokinin 2 receptor Synthesis and evaluation of dimeric derivatives of 5-HT(2A) receptor (5-HT(2A)R) antagonist M-100907.Synthesis and bioactivity of MSH4 oligomers prepared by an A2 + B2 strategy.Fluorescent and lanthanide labeling for ligand screens, assays, and imaging.Cell-specific targeting by heterobivalent ligands.A Synthetic Heterobivalent Ligand Composed of Glucagon-Like Peptide 1 and Yohimbine Specifically Targets β Cells Within the Pancreas Design, synthesis, and biological studies of efficient multivalent melanotropin ligands: tools toward melanoma diagnosis and treatment.Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances.Trigonal scaffolds for multivalent targeting of melanocortin receptors.Peptide heterodimers for molecular imaging.Tumor Targeting and Pharmacokinetics of a Near-Infrared Fluorescent-Labeled δ-Opioid Receptor Antagonist Agent, Dmt-Tic-Cy5.Synthesis and characterization of time-resolved fluorescence probes for evaluation of competitive binding to melanocortin receptors Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy.Synthetic receptors with antibody-like binding affinities.Principles and emerging applications of nanomagnetic materials in medicine.Radiolabeled heterobivalent peptidic ligands: an approach with high future potential for in vivo imaging and therapy of malignant diseases.Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016.NIR-activated content release from plasmon resonant liposomes for probing single-cell responses.Iodine 125-labeled mesenchymal-epithelial transition factor binding peptide-click-cRGDyk heterodimer for glioma imaging.

P2860

Q33555093-53AD5189-9E8E-4E13-B68C-EB3AF26C2B06 Q33715334-7986BFC4-0738-42FD-9E83-0B0F622852B1 Q33732587-7D4B6462-57D2-4D88-B5AC-349C0F99E124 Q33803703-4DA8AE4B-B3E5-43AA-BB5A-13326E688766 Q33925013-FC141D22-19A7-44CE-868E-16FE32EF9508 Q34028115-C7262075-11C5-4AE5-A842-7FE4A58EAEFA Q34039390-D8BD4874-3766-4A4B-93C5-2E6E53F6C690 Q34317386-D24BF8F6-ADB6-4265-9B4B-9C3C84B85A93 Q34359984-33403864-5FD6-405B-8E19-574D20B82328 Q35235477-2CFE68E6-733F-475A-AE8C-07E0B8720359 Q35661784-78A4B9DC-B368-4D00-A0B8-ABCDF8AC988B Q35781719-C151CFD1-F707-45DF-82D3-E540BF89BDCD Q36003339-D398801C-79D3-4F58-B8D7-C222F450AC70 Q36055049-B7D8ABAA-2EB9-4C2D-B80C-C56D72A394C3 Q36395175-12C4025F-DEA1-4178-8A23-3FB8308A9FC5 Q36464806-20556CA7-EBD0-4789-8AFE-00AD2152AD40 Q36589179-95E9719A-169C-49E8-83F3-BE80B5E5A85A Q36658378-AD9FED27-1F90-47A9-89C8-CA019ED307F5 Q36746620-56B5A186-42FC-4559-AEB7-F4CAE9AA6F81 Q37075319-070AC79C-445D-4773-BBD2-0322E6F8A153 Q37173854-4D8B13C0-EDA4-477E-9031-510A717796A8 Q37389360-25D91DE5-909C-470E-ADBA-55ADD4DEB935 Q37776862-26B68DD2-C6C1-41CC-82D4-864623E82713 Q38001396-D61F4D3C-F188-428D-9269-9C5E4CAEDC5D Q38096994-B54B6792-8D1A-4187-B63C-8E01DAF87151 Q39211934-A6890E61-6CCC-4C0D-A2D7-D2B98D6EC6F1 Q41761358-03118E11-182E-4A8D-B47C-23EA90642575 Q53224886-87D41ED2-5335-4991-9AAB-EC68224E6FEF

P2860

Enhanced targeting with heterobivalent ligands

http://www.wikidata.org/entity/Q36870878

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Enhanced targeting with heterobivalent ligands

@en

type

label

Enhanced targeting with heterobivalent ligands

@en

prefLabel

Enhanced targeting with heterobivalent ligands

@en

P1433

Q36870878-145F3A4F-0CF2-41CB-8650-BBC2FFFA6658

P1476

Q36870878-5A71D62E-454F-4EF8-AD70-E73BB7312129

P2093

Q36870878-696AB49C-46CA-4262-B248-5AFE2E1A5883

Q36870878-6EDD06C7-0A8A-4458-B382-AAFE866C6D07

Q36870878-77545B29-8170-41E5-92B6-C213F5405051

Q36870878-A4DAE716-7D6B-44CD-9091-14F85A510DAC

Q36870878-B06FC4F6-4AEB-4608-BAB4-B0798A47008C

Q36870878-B622DAA6-0545-415C-B90A-B878E4E86C6F

Q36870878-C662AAF3-2D07-4DF5-952E-0AE538700AFA

Q36870878-D5F63574-15E2-4F87-B884-FE9A53507966

Q36870878-E175F8BD-E887-43B1-B99A-41D700495F6C

Q36870878-E82609FD-ECDE-40C9-BDC8-C0B090345CFA

P2860

Q36870878-0082E6BA-8C30-4858-AB7F-1B5509469EF9

Q36870878-0E85E4C4-1016-4584-9207-64CD4D59C174

Q36870878-0F1FA02C-3363-4426-B40E-723C8741D189

Q36870878-15B509D6-267E-4821-AB43-B59C2822AC2C

Q36870878-1E047DFC-A285-4CBF-961A-AA5C3B95C561

Q36870878-20051A56-4CA4-4DDA-B9E2-AF4D4E848414

Q36870878-25A99685-4A9C-423A-B930-E02BF526A9C1

Q36870878-2C970704-542A-48C5-8162-440508E7CC7F

Q36870878-364C47A4-967B-41C9-8F66-C92089704559

Q36870878-36E9C4D3-B680-41DC-84D5-366E577470F5

P304

Q36870878-47E4F472-D585-4B8F-93CB-E7AD10F3728C

P31

Q36870878-BCBC7AB1-6A37-4303-AE54-4622F9ACF55B

P356

Q36870878-12A4905E-8501-4E99-A25E-35498A970E78

P433

Q36870878-03E13B70-A4CE-4AB3-AC40-2DCB4F485244

P478

Q36870878-1679D5F1-8FF0-4BB3-8CF8-BC0232DA6347

P577

Q36870878-FA23E606-90C0-4FCA-82E3-BCCC85C71793

P698

Q36870878-9144C1DD-FC1C-4146-960E-3753DFE74BA1

P932

Q36870878-40402959-2A54-4566-8BEC-F9DC160FA255

P356

1535-7163.MCT-08-1183

P1433

Molecular Cancer Therapeutics

P1476

Enhanced targeting with heterobivalent ligands

@en

P2093

Brenda Baggett

http://www.w3.org/2001/XMLSchema#string

David L Morse

http://www.w3.org/2001/XMLSchema#string

Eugene A Mash

http://www.w3.org/2001/XMLSchema#string

Haiyong Han

http://www.w3.org/2001/XMLSchema#string

Jatinder Josan

http://www.w3.org/2001/XMLSchema#string

Josef Vagner

http://www.w3.org/2001/XMLSchema#string

Liping Xu

http://www.w3.org/2001/XMLSchema#string

Robert J Gillies

http://www.w3.org/2001/XMLSchema#string

Ronald M Lynch

http://www.w3.org/2001/XMLSchema#string

Victor J Hruby

http://www.w3.org/2001/XMLSchema#string

P2860

Hetero-oligomerization between beta2- and beta3-adrenergic receptors generates a beta-adrenergic signaling unit with distinct functional properties

Lanthanide-based time-resolved fluorescence of in cyto ligand-receptor interactions.

The inhibition of lung cancer cell growth by intracellular immunization with LC-1 ScFv.

Development of a lanthanide-based assay for detection of receptor-ligand interactions at the delta-opioid receptor.

A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases.

Synthetic multivalent ligands in the exploration of cell-surface interactions.

Design and application of diabodies, triabodies and tetrabodies for cancer targeting.

Target discovery.

Detection of promoter activity by flow cytometric analysis of GFP reporter expression.

Her-2/neu and breast cancer.

P304

2356-2365

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-08-1183

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19671749

http://www.w3.org/2001/XMLSchema#string

P932

3662534

http://www.w3.org/2001/XMLSchema#string